Methylation of the genes in the 9P21 region in children with acute myeloid leukemia
ZHANG Li, RUAN Min, LIU Xiao-Ming, ZHANG Jia-Yuan, GUO Ye, YANG Wen-Yu, LIU Fang, LIU Tian-Feng, WANG Shu-Chun, CHEN Xiao-Juan, ZOU Yao, CHEN Yu-Mei, ZHU Xiao-Fan
Department of Pediatrics, Institute of Hematology, Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin 300020, China
Abstract：Objective To investigate the methylation rate of cyclin-dependent kinase inhibitor 2A (CDKN2A) and cyclin-dependent kinase inhibitor 2B (CDKN2B) in the 9P21 region in children with acute myeloid leukemia (AML) and the association of gene methylation with clinical features and outcomes. Methods The clinical data of 58 children who were newly diagnosed with AML between January 2010 and December 2012 were retrospectively analyzed. Thirtyeight healthy children were recruited as the control group. Genomic DNA was extracted from bone marrow or peripheral blood of the 58 patients and 38 healthy children. The methylation status of CDKN2A and CDKN2B was analyzed by methylation-specific multiplex ligation-dependent probe amplification. Results Gene methylation was not found in healthy children. Methylation probes of 44 patients were detected in 58 patients. The methylation of CDKN2A was detected with 136 bp and 237 bp methylation probes. The methylation of CDKN2B was detected with 130 bp, 210 bp, 220 bp, and 417 bp methylation probes. The methylation rate of CDKN2A was 5%, while the methylation rate of CDKN2B was 76%. The methylation detected by some probes was associated with sex, hemoglobin, and platelet count at the first visit. Conclusions The methylation of CDKN2B is a common event in children with AML, while the methylation of CDKN2A is relatively rare.
ZHANG Li,RUAN Min,LIU Xiao-Ming et al. Methylation of the genes in the 9P21 region in children with acute myeloid leukemia[J]. CJCP, 2015, 17(1): 6-10.
Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties[J]. Blood, 1998, 92(7): 2322-2333.
[3]
李玉华, 文飞球. DNA 甲基化与儿童白血病的临床研究进展[J]. 中国当代儿科杂志, 2011, 13(2): 174-177.
[4]
Schoofs T, Berdel WE, Müller-Tidow C. Origins of aberrant DNA methylation in acute myeloid leukemia[J]. Leukemia, 2014, 28(1): 1-14.
[5]
Jasielec J, Saloura V, Godley LA. The mechanistic role of DNA methylation in myeloid leukemogenesis[J]. Leukemia, 2014, 28(9): 1765-1773.
[6]
Das PM, Singal R. DNA methylation and cancer[J]. J Clin Oncol, 2004, 22(22): 4632-4642.
[7]
Galm O, Wilop S, Lüders C, et al. Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia[J]. Ann Hematol, 2005, 84 Suppl 1: 39-46.
[8]
Agrawal S, Unterberg M, Koschmieder S, et al. DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia[J]. Cancer Res, 2007, 67(3): 1370-1377.
[9]
Recio JA, Noonan FP, Takayama H, et al. Ink4a/arf deficiency promotes ultraviolet radiation-induced melanomagenesis[J]. Cancer Res, 2002, 62(22): 6724-6730.
[10]
Bazan V, Zanna I, Migliavacca M, et al. Prognostic significance of p16INK4a alterations and 9p21 loss of heterozygosity in locally advanced laryngeal squamous cell carcinoma[J]. J Cell Physiol, 2002, 192(3): 286-293.
Cechova H, Lassuthova P, Novakova L, et al. Monitoring of methylation changes in 9p21 region in patients with myelodysplastic syndromes and acute myeloid leukemia[J]. Neoplasma, 2012, 59(2): 168-174.
[13]
Tsukimoto I, Tawa A, Horibe K, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group[J]. J Clin Oncol, 2009, 27(24): 4007-4013.
[14]
Mrózek K, Marcucci G, Paschka P, et al. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?[J]. Blood, 2007, 109(2): 431-448.
[15]
Caiafa P, Zampieri M. DNA methylation and chromatin structure: the puzzling CpG islands[J]. J Cell Biochem, 2005, 94(2): 257-265.
[16]
Herman JG, Graff JR, Myöhänen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands[J]. Proc Natl Acad Sci U S A, 1996, 93(18): 9821-9826.
[17]
Tien HF, Tang JH, Tsay W, et al. Methylation of the p15(INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation[J]. Br J Haematol, 2001, 112(1): 148-154.
[18]
Chim CS, Kwong YL. Adverse prognostic impact of CDKN2B hyper-methylation in acute promyelocytic leukemia[J]. Leuk Lymphoma, 2006, 47(5): 815-825.
[19]
Au WY, Fung AT, Ma ES, et al. Serial studies of methylation of CDKN2B and CDKN2A in relapsed acute promyelocytic leukaemia treated with arsenic trioxide[J]. Br J Haematol, 2005, 131(5): 632-635.
[20]
Markus J, Garin MT, Bies J, et al. Methylation-independent silencing of the tumor suppressor INK4b (p15) by CBFbeta-SMMHC in acute myelogenous leukemia with inv(16)[J]. Cancer Res, 2007, 67(3): 992-1000.
Pleyer L, Burgstaller S, Girschikofsky M, et al. Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group[J]. Ann Hematol, 2014, 93(11): 1825-1838.
